2019 年博士毕业于英国伦敦大学学院（University College London）有机化学专业，导师 Jim Anderson 教授（FRSC，英国皇家化学会会士），主要从事活性单萜吲哚生物碱的全合成研究。2020 年入职中国药科大学工学院，现任副教授，兴药副研究员。

研究/项目简介：

1，复杂天然产物/活性药物全合成开发与产业化，聚焦具有多种药理活性的复杂吲哚生物碱、前列腺素类化合物的工艺研究与创新衍生；

2，分子荧光探针的开发与应用评价

2021年获江苏省“双创博士”，主持国家自然科学基金青年项目一项（2021-2023）、主持国家自然科学基金面上项目一项（2026-2029），中央高校基本科研业务经费重点项目一项；

2026 年招生方向：1）生物医学工程（学硕）；2）制药工程学（学硕）

论文发表详见ORCID:

https://orcid.org/0000-0002-5273-4765 

代表性工作：

(1)  Xinyu Zhu, Zhihao Qi, Jingfan Pan, Sheng Jiang, Ting Wang, Taobin Chen*, Tianyu Wang*, Xiangyu Zhang*, Seeking Equality from an Asymmetric System: The Convergent Total Synthesis of Prostacyclin Drug (±)-Beraprost Sodium Org. Lett. 2026 ASAP [https://pubs.acs.org/doi/10.1021/acs.orglett.5c05111  ]

(2) Qing Li, Yuting Zhao, Xinyu Zhu, Sheng Jiang, Tianyu Wang, Dawei Deng*, Xiangyu Zhang*, Traceless Nitro Group Directing Strategy: Modular Syntheses of the Scaffolds of Polycyclic Alkaloids Org. Lett. 2025, 27, 7863-7869  (封面文章) [https://pubs.acs.org/doi/10.1021/acs.orglett.5c02174  ]

(3)  Zhihao Qi, Yao Cheng, Kaizhen Wang, Shi Cai, Xiang Ni, Tianyu Wang, Kuojun Zhang, Sheng Jiang*, Yibei Xiao*, and Xiangyu Zhang*, Discovery, Synthesis, and Activity Evaluation of Novel Small-Molecule Inhibitors Targeting VISTA for Cancer Immunotherapy J. Med. Chem. 2025, 68, 5222-5237. [https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02031  ]

(4)  Xiangyu Zhang; Vallesamidine and schizozygane alkaloids: rearranged monoterpene indole alkaloids and synthetic endeavours, Nat. Prod. Rep. 2024, 41, 784. [https://doi.org/10.1039/D3NP00048F  ]

(5)  Kaizhen Wang, Shi Cai, Yao Cheng, Zhihao Qi, Xiang Ni, Kuojun Zhang, Yibei Xiao,* Xiangyu Zhang,* Tianyu Wang* Discovery of Benzo[d]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway J. Med. Chem. 2024, 67, 18526–18548. [https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c01899  ]

(6)Tianyu Wang; Kaizhen Wang; Yu Zhang; Kuojun Zhang; Shi Cai; Sheng Jiang*; Yibei Xiao*; Xiangyu Zhang*; Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA). J. Med. Chem. 2023, 66, 11881-11892. [https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00484  ]

(7) Kaizhen Wang¹; Xiangyu Zhang¹; Yao Cheng¹; Zhihao Qi¹; Ke Ye; Kuojun Zhang; Sheng Jiang; Yi Liu; Yibei Xiao; Tianyu Wang; Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy.  J. Med. Chem. 2023, 66, 16807-16827. [https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c01534  ]

(8) Kuojun Zhang; Tianyu Wang; Maotian Li; Mu Liu; He Tang; Lin Wang; Ke Ye; Jiamei Yang; Sheng Jiang; Yibei Xiao; Youhua Xie; Meiling Lu; Xiangyu Zhang; Discovery of quinazolin-4-onebased non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro).  Eur. J. Med. Chem. 2023, 257: 115487. 

(9) Shi Cai; Kaizhen Wang; Zhihao Qi; Ke Ye; Xinyuan Zhou; Sheng Jiang; Kuojun Zhang*; Xiangyu Zhang*; Tianyu Wang*, Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold.  Eur. J. Med. Chem. 2023, 256, 115468. [https://www.sciencedirect.com/science/article/pii/S0223523423004531  ]

(10) Xiangyu Zhang; James C. Anderson, A Divergent Synthetic Route to the Vallesamidine and Schizozygine Alkaloids: Total Synthesis of (+)-Vallesamidine and (+)-14,15-Dehydrostrempeliopine., Angew. Chem. Int. Ed. 2019, 58, 18040-18045 [https://onlinelibrary.wiley.com/doi/10.1002/anie.201910593  ]